Cymabay Therapeutics Inc represents a commitment to scientific innovation and patient-centric care. With a focus on developing breakthrough therapies for liver and metabolic diseases, the company aims to improve the lives of patients worldwide. Cymabay Therapeutics Inc operates with a strong corporate philosophy, emphasizing collaboration, integrity, and a dedication to delivering high-quality solutions. By staying at the forefront of research and leveraging cutting-edge technologies, Cymabay Therapeutics Inc strives to address unmet medical needs and create lasting value for patients, healthcare providers, and shareholders alike.

Cymabay Therapeutics Inc primarily operates and has a presence in various countries and regions worldwide. These include the United States, where the company is headquartered in Newark, California. Additionally, Cymabay Therapeutics Inc extends its operations and engages in activities across Europe and Asia. The company has established partnerships and collaborations that further expand its global reach. As a reputable biopharmaceutical company, Cymabay Therapeutics Inc focuses on developing breakthrough therapies and innovative solutions for various medical conditions.

Cymabay Therapeutics Inc has achieved significant milestones in its journey. The company successfully completed Phase 2 clinical trials for its lead product candidate, Seladelpar, indicating positive results in treating primary biliary cholangitis (PBC). Additionally, Cymabay received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for Seladelpar's development. The company has also made noteworthy progress in expanding its pipeline with advancements in exploring novel conjugated bile acids for various liver diseases. Cymabay's commitment to innovation and dedication to improving patient outcomes showcases its success in the biopharmaceutical industry.

Cymabay Therapeutics Inc is a biopharmaceutical company specializing in the research and development of therapies for liver and metabolic diseases. Founded in 1988, the company has a rich history of advancing innovative drug candidates towards commercialization. Cymabay Therapeutics Inc focuses on developing potent and selective small molecules that target key biological pathways to address unmet medical needs. With a strategic focus on liver and metabolic diseases, Cymabay Therapeutics Inc aims to improve patient outcomes and quality of life. This California-based company has a diverse pipeline of investigational drugs, including seladelpar, a potential treatment for primary biliary cholangitis and nonalcoholic steatohepatitis.

The main competitors of Cymabay Therapeutics Inc in the market include Biogen Inc, Intercept Pharmaceuticals Inc, and Galectin Therapeutics Inc.

Cymabay Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Cymabay Therapeutics Inc is focused on developing and commercializing innovative therapies for patients with liver and metabolic diseases. Cymabay Therapeutics Inc aims to discover, develop, and bring to market therapies that can address significant unmet medical needs. Through its research and development efforts, Cymabay Therapeutics Inc strives to develop novel small molecules that target specific disease pathways and have the potential to provide patients with improved outcomes. By leveraging its expertise and collaborative partnerships, Cymabay Therapeutics Inc aims to deliver transformative treatments to patients worldwide.

CymaBay Therapeutics için şu anki KGV hesaplanamıyor.

CymaBay Therapeutics için mevcut KUV şu anda hesaplanamıyor.

CymaBay Therapeutics için AlleAktien Kalite Skoru 4/10'dur.

CymaBay Therapeutics için şu an ciro hesaplanamıyor.

CymaBay Therapeutics için şu anda kar hesaplanamıyor.

Cymabay Therapeutics Inc is a biopharmaceutical company that focuses on the development of therapeutics for the treatment of severe metabolic diseases. Its business model is based on the discovery and development of novel chemicals that can selectively influence specific receptors in the body and regulate metabolic processes. The company specializes in various areas, including the analysis of metabolic disorders, elucidation of signaling pathways, and drug development. Cymabay works closely with scientists and medical experts to ensure the effectiveness and safety of its products. Cymabay's focus is on the treatment of chronic metabolic diseases, such as primary biliary cholangitis, an inflammation of the bile ducts, and lipodystrophy, an extremely rare alteration of fat metabolism. Cymabay's products aim to alleviate the symptoms of these diseases and improve patients' quality of life. One of Cymabay's key products is arhalofenate, an anti-inflammatory medication used in the treatment of primary biliary cholangitis. Arhalofenate specifically targets the cellular signaling pathway that triggers inflammation in the bile ducts and can therefore alleviate the symptoms of the disease. The medication is currently in Phase 3 of clinical development. Another promising product from Cymabay is seladelpar, a medication for the treatment of metabolic diseases such as non-alcoholic fatty liver disease and primary biliary cholangitis. Seladelpar acts on the nuclear receptor PPAR-delta, which plays an important role in the regulation of metabolic processes. In clinical studies, the medication has shown significant reduction of liver enzymes and fat deposits in the liver. Seladelpar is currently in Phase 2b of clinical development. Cymabay's business model is based on the development of innovative therapeutics that offer real benefits to patients due to their targeted effects and high efficacy. The company relies on close collaborations with scientists and medical experts to drive the development of its products. Overall, Cymabay Therapeutics Inc is a promising company in the field of metabolic diseases that can make a significant contribution to improving the health of millions of people with its innovative products. With a clear focus on patient needs and a strong scientific foundation, the company is well positioned to succeed in the market.

CymaBay Therapeutics, yılda kez dağıtılmak üzere 0 USD tutarında temettü ödemektedir.

CymaBay Therapeutics için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

CymaBay Therapeutics şirketinin ISIN kodu US23257D1037’dir.

CymaBay Therapeutics 'nin WKN'si A116DD 'dir.

CymaBay Therapeutics için Ticker CBAY’dir.

Son 12 ay içerisinde CymaBay Therapeutics, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için CymaBay Therapeutics, tahmini olarak 0 USD tutarında bir temettü ödemesi yapacak.

CymaBay Therapeutics şirketinin mevcut temettü verimi .

CymaBay Therapeutics dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

CymaBay Therapeutics, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 USD tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

CymaBay Therapeutics, 'Sağlık' sektörüne atanmıştır.

Son CymaBay Therapeutics tarihinde 0 USD tutarındaki en son temettüyü alabilmek için, hisseyi 04.10.2024 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 04.10.2024 olarak gerçekleşti.

2023 yılında CymaBay Therapeutics tarafından 0 USD olarak temettüler dağıtıldı.

CymaBay Therapeutics hisselerinin temettüleri USD olarak dağıtılır.